Cannabis ETFs Spike on Jazz-GW Pharma Deal – February 4, 2021

Cannabis stocks have now been the largest champions to begin 2021 buoyed by hopes of wider legalization and decriminalization that is near-term well as the growing adoption of marijuana in more states. The recent comments from several prominent politicians regarding cannabis reform legislation added to the strength (read: 5 ETF that is best spending Tips for 2021).

In reality, a few Democratic senators released a statement that is joint this week signaling plans of pursuing new legislation to reform regulations in the United States. The deal activity that is latest within the area has strengthened the bullish instance of these shares. This is especially valid as Jazz Pharmaceuticals ( Free Report) for $7.2 billion in cash and stock.Deal in Focus

Per the terms of the deal, Jazz will pay $220 per American depositary share of GW Pharmaceuticals, including $200 in cash and $20 in Jazz ordinary shares. This represents a premium of about 50% over GWPH’s closing price on Feb 2, and 60% over its 30-day volume weighted price that is average. The offer is respected at $6.7 billion internet of GW cash.

The combined business will undoubtedly be a leader in neuroscience with an international professional and footprint that is operational. The deal will bolster GWPH’s efforts in developing, manufacturing and…

Original Author Link click here to read complete story..

Cannabis stocks have been the biggest winners to start 2021 buoyed by hopes of wider legalization and near-term decriminalization as well as the growing adoption of marijuana in more states. The recent comments from several prominent politicians regarding cannabis reform legislation added to the strength (read: 5 ETF that is best spending Tips for 2021).

In reality, a few Democratic senators released a statement that is joint this week signaling plans of pursuing new legislation to reform regulations in the United States. The deal activity that is latest within the area has strengthened the bullish instance of these shares. This is especially valid as Jazz Pharmaceuticals (

JAZZ fast Quote(* that is*)JAZZ( – Free Report) agreed to buy cannabinoid drug company GW Pharmaceuticals ( GWPH Quick QuoteGWPH Free Report) for $7.2 billion in cash and stock. Deal in FocusPer the terms of the deal, Jazz will pay $220 per American depositary share of GW Pharmaceuticals, including $200 in cash and $20 in Jazz ordinary shares. This represents a premium of about 50% over GWPH’s closing price on Feb 2, and 60% over its 30-day volume weighted price that is average. The offer is respected at $6.7 billion internet of GW cash.

The combined business will undoubtedly be a leader in neuroscience with an international professional and footprint that is operational. The deal will bolster efforts that are GWPH’s developing, manufacturing and…

Source website link

Latest posts